Symprove, Audited: The UK Probiotic Giant Coming to America
In January an American supplement group bought the UK’s cult refrigerated probiotic and pointed it at the US market. Before the ads arrive, read the file: it contains the rarest thing in the aisle — a real symptom trial — and the fine print the marketing will skip.
Symprove is a UK-made, water-based, barley-derived liquid probiotic taken as a refrigerated 70 mL morning shot, acquired in January 2026 by US supplement group Metagenics with stated plans for international expansion through healthcare practitioners. Its evidence file holds something almost no consumer probiotic has: a randomized, double-blind, placebo-controlled trial with a met symptom endpoint. In the 2014 King's College London study of 186 IBS patients over 12 weeks, symptom severity scores fell 63.3 points on Symprove versus 28.3 on placebo — a 35-point between-group difference, p=0.01 — with no serious adverse events. The same paper's fine print: single centre, 34 dropouts, and no significant quality-of-life improvement. A second randomized trial in 2019 gave 81 ulcerative colitis and 61 Crohn's patients four weeks of the liquid: the inflammation marker faecal calprotectin fell significantly in ulcerative colitis only, with no symptom or quality-of-life differences in either disease. That is the whole published randomized record — one good symptom trial from 2014 carrying the brand for a decade, with a coeliac trial registered and underway. IBS and IBD care decisions belong with a clinician. Educational, not medical advice.
The most interesting probiotic company in America right now is one most Americans have never heard of. Symprove is a British brand — a peculiar one by US standards: a liquid you swig each morning like a 70-millilitre shot, kept in the fridge, built on barley, and carrying a cult following of UK gastro patients and dietitians. In January, the American supplement group Metagenics acquired it, with stated plans to push it through its global network of healthcare practitioners. Translation: this brand is coming to a shelf, a feed and possibly a clinician’s recommendation near you. So before the marketing arrives, here is the audit — because Symprove’s evidence file contains something genuinely rare in this aisle, and the rare thing is not what its ads will lead with.
The rare thingThe symptom trial almost nobody else has
Across this series, one refrain keeps repeating: probiotic companies test biomarkers, not how people feel. Symprove is the exception. In a 12-week randomized, double-blind, placebo-controlled trial run at King’s College London and published in Alimentary Pharmacology & Therapeutics, 186 patients with symptomatic IBS took the liquid daily or a matched placebo. The primary endpoint was the thing that actually matters — the IBS Symptom Severity Score — and it was met: symptoms fell 63.3 points on Symprove versus 28.3 on placebo, a between-group difference of 35 points (p = 0.01), with no serious adverse events. A real symptom outcome, in real patients, against placebo, in a major gastroenterology journal. Neither Seed nor Pendulum has published its equivalent.
The asterisksWhat the same trial says in its fine print
Read closely, the trial also hands over its own caveats. It was a single-centre study — one hospital, one team — and 34 of the 186 randomized patients did not complete it. The 35-point average between-group difference is real but modest against the placebo arm’s own 28-point drift, a reminder of how strong the placebo response runs in IBS. And the quality-of-life score, a secondary endpoint, did not significantly improve — symptoms moved; how patients rated their lives did not. None of this undoes the result. It sizes it: one good trial, from 2014, that has been carrying the brand’s scientific reputation for over a decade without a published replication at the same standard.
One well-run symptom trial from 2014 has carried this brand for a decade. In this industry, that is somehow still the record.
The second trialThe IBD study, honestly told
Symprove’s other randomized outing is instructive in the opposite direction. In a 2019 placebo-controlled trial, 81 patients with quiet ulcerative colitis and 61 with Crohn’s disease took the probiotic or placebo for four weeks. The result was a biomarker story, not a symptom one: faecal calprotectin — a stool marker of gut inflammation — fell significantly in the ulcerative colitis group (p < 0.015), while Crohn’s patients showed no significant change and neither group reported quality-of-life differences. An anti-inflammatory signal in UC is genuinely interesting; it is also exactly the kind of finding that gets compressed into “proven for gut inflammation” by the time it reaches a social caption. The register matters: nobody with IBD should be swapping medication for a barley drink, and the trial never claimed otherwise.
The next chapterWhat the acquisition changes
Until now, Symprove’s story has been evidence-forward by necessity — a small UK company selling an odd refrigerated liquid had nothing else to sell it with, and it kept running studies, including a registered coeliac disease trial currently underway. Under a US owner built on practitioner distribution, the incentives shift: the same modest file of evidence will now be asked to support a much louder, much wider push. The 2014 trial will appear everywhere; the null quality-of-life line, the single centre, and the four-week IBD timeframe will appear nowhere. You now have both halves. When the brand shows up in your feed with “clinically proven” on it — and it will — you know precisely which clinic, which 186 people, and which 35 points are doing the proving. This audit is part of Gut Check, our running evidence review of the gut-health industry. It is educational and is not medical advice; IBS and IBD care decisions belong with your clinician.